Practically Speaking: Adjuvant Immunotherapy for High Risk Resected UCC

To be added to the distribution list, please email: DDeCastro@southlakeregional.org

In this episode, Dr. Srikala Sridhar will discuss how to incorporate adjuvant Immunotherapy into the treatment landscape for high risk resected UCC. 

Key Opinion Leader: 
Dr. Srikala Sridhar MD. MSc. FRCPC

Professor of Medicine, University of Toronto
Medical Oncologist, Princess Margaret Cancer Centre
Chair - Genitourinary Medical Oncologists of Canada 
Vice Chair of the Medical Advisory Board of Bladder Cancer Canada. 
CCTG, GU Disease Site Executive Committee and the US NCI Bladder Cancer Task Force.

Host:
Dr. Shaqil Kassam MD. MSc. FRCPC
skassam@southlakeregional.org
Medical Oncologist
Stronach Regional Cancer Centre, Newmarket, Ontario 

Outline:
0:00 - Introduction
1:40  – Dr. Kala Sridhar - Biography
3: 10 – Is adjuvant Nivo standard of care for high risk resected MIUC
6: 35 - Checkmate 274 vs. Imvigor 010 vs. Ambassador
12:50 - Discussion about specific neo-adjuvant options
20:10 - Practical Implementation of Checkmate 274 into daily practice. 
23:30 - Getting into sub-groups (Upper tract, mixed histology and PDL<1%)
29:00 - What to do for relapsed disease

Previous episodes: https://www.blogtalkradio.com/medoncnow